Beyond providing state-of-the-art medical and surgical care to patients in our well-equipped offices, the physicians in our clinic initiate and participate in multiple clinical trials sponsored by the NIH and pharmaceutical industries, so patients referred to our clinic have access to cutting-edge technologies and medications through enrollment in these studies. Our study department employs full time study coordinators, EMMES certified refractionists, as well as certified study technicians and photographers to ensure top quality-of-care for our patients.
The following is a partial list of the clinical trials in our clinic:
A) Clinical trials that are completed or near completion
DNIH’s DRCR.net Protocol N – Intravitreal ranibizumab for vitreous hemorrhage from proliferative diabetic retinopathy (PDR).
NIH’s DRCR.net Protocol P – Cataract surgery with center-involved diabetic macular edema (DME) Study.
NIH’s DRCR.net Protocol Q – Cataract surgery without center-involved diabetic macular edema (DME) Study.
NIH’s AREDS II for AMD and ancillary Studies
Genentech’s RIDE Study for patients with diabetic macular edema
IST supported by Genentech for treatment of vascularized pigment epithelial detachment (PED) due to AMD with 0.5 vs. 2.0 mg ranibizumab
B) Ongoing clinical trials
NIH’s DRCR.net Protocol R – Phase II non-central diabetic macular edema (DME) and non-steroidal anti-inflammatory drug (NSAID) Study
NIH’s DRCR.net Protocol S – Prompt panretinal photocoagulation (PRP) vs. ranibizumab and deferred PRP for PDR Study.
NIH’s DRCR.net Protocol T – Aflibercept, bevacizumab and ranibizumab comparison for DME Study
Regeneron’s VIBRANT Study for patients with naïve branch retinal vein occlusion (BRVO) and macular edema.
Regeneron’s RE-VIEW-AMD 1124 study.
IST supported by Regeneron for treatment of vascularized PED due to AMD with aflibercept, a multi-modal
Independent IST for investigating intraocular drug level for patients treated with aflibercept
Retrospective study for patients treated with aflibercept who were previously on bevacizumab or ranibizumab
EMD Serono’s Egrifta (Tesamorelin) for HIV patients with lipodystrophy.
Dr. Chan's latest published clinical study
Earlier therapeutic effects associated with high dose (2.0mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in agerelated macular degeneration
If you are interested in learning more about clinical trials please call the office and ask to speak to a study coordinator, 760-340-2394.